Jeetinder Singh Mahal net worth and biography

Jeetinder Mahal Biography and Net Worth

Mr. Mahal joined Jasper Therapeutics as Chief Financial and Business Officer from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa^®, Bevyxxa^® and cerdulatinib. He also played a key role in the company’s equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto^® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics.

What is Jeetinder Singh Mahal's net worth?: The estimated net worth of Jeetinder Singh Mahal is at least $15.64 thousand as of December 12th, 2024. Mr. Mahal owns 25,009 shares of Jasper Therapeutics stock worth more than $15,641 as of September 30th. This net worth approximation does not reflect any other assets that Mr. Mahal may own. Learn More about Jeetinder Singh Mahal's net worth.
How do I contact Jeetinder Singh Mahal?: The corporate mailing address for Mr. Mahal and other Jasper Therapeutics executives is 2200 Bridge Pkwy Suite #102, Redwood City, CA, 94065. Jasper Therapeutics can also be reached via phone at 650-549-1400 and via email at [email protected]. Learn More on Jeetinder Singh Mahal's contact information.
Has Jeetinder Singh Mahal been buying or selling shares of Jasper Therapeutics?: Jeetinder Singh Mahal has not been actively trading shares of Jasper Therapeutics during the last quarter. Most recently, Jeetinder Singh Mahal sold 900 shares of the business's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $22.11, for a transaction totalling $19,899.00. Following the completion of the sale, the chief operating officer now directly owns 25,009 shares of the company's stock, valued at $552,948.99. Learn More on Jeetinder Singh Mahal's trading history.

Jeetinder Singh Mahal Insider Trading History at Jasper Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/12/2024	Sell	900	$22.11	$19,899.00	25,009
9/12/2024	Sell	900	$21.23	$19,107.00	25,009
6/12/2024	Sell	900	$24.16	$21,744.00	25,009
3/12/2024	Sell	900	$26.44	$23,796.00	25,009
6/13/2023	Sell	900	$16.60	$14,940.00	28,722

Jeetinder Singh Mahal Buying and Selling Activity at Jasper Therapeutics

Jasper Therapeutics Company Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Today's Range

Now: $0.63

$0.62

$0.63

50 Day Range

MA: $0.69

$0.57

$0.89

2 Week Range

Now: $0.63

$0.32

$2.69

Volume

2,992 shs

Average Volume

849,337 shs

Market Capitalization

$21.03 million

P/E Ratio

N/A

Dividend Yield